Literature DB >> 2230837

Central nervous system involvement in nephropathic cystinosis.

D G Vogel1, M H Malekzadeh, M E Cornford, J A Schneider, W D Shields, H V Vinters.   

Abstract

Nephropathic cystinosis, an autosomal recessive lysosomal storage disorder due to impaired cystine transport, causes damage to multiple organs that results in end-stage renal disease, hypothyroidism, and retinopathy, usually in childhood. Dialysis and renal transplantation now frequently enable patients with cystinosis to live into adulthood. Examinations at autopsy of a 28-year-old man who died of complications of this disease showed deposits of cystine crystals in multiple organs. There was severe cerebral involvement with multifocal cystic necrosis, dystrophic calcification, spongy change, and vacuolization that had produced profound neurologic deficits. Electron microscopy of the brain documented cytoplasmic deposition of cystine crystals in membrane bound vacuoles within the cytoplasm of pericytes and within parenchymal cells of the white matter. While affected patients who have received renal transplants may no longer die from renal failure, serious, potentially life-threatening, neurologic complications of this disorder may supervene.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2230837     DOI: 10.1097/00005072-199011000-00005

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  20 in total

1.  Visual and verbal learning in a genetic metabolic disorder.

Authors:  Amy M Spilkin; Angela O Ballantyne; Doris A Trauner
Journal:  Neuropsychologia       Date:  2009-03-09       Impact factor: 3.139

2.  Association of Nephropathic Cystinosis and Pseudotumor Cerebri with Bilateral Duane Syndrome Type I.

Authors:  Bahareh Behdad; Abbas Bagheri; Mehdi Tavakoli; Mohammad Pakravan
Journal:  Neuroophthalmology       Date:  2014-02-07

3.  Hierarchical processing of visual stimuli in nephropathic cystinosis.

Authors:  Aakash Sathappan; Doris Trauner
Journal:  J Inherit Metab Dis       Date:  2019-02-19       Impact factor: 4.982

4.  Executive function in nephropathic cystinosis.

Authors:  Angela O Ballantyne; Amy M Spilkin; Doris A Trauner
Journal:  Cogn Behav Neurol       Date:  2013-03       Impact factor: 1.600

5.  Neurological impairment in nephropathic cystinosis: motor coordination deficits.

Authors:  Doris A Trauner; Jennifer Williams; Angela O Ballantyne; Amy M Spilkin; Jennifer Crowhurst; John Hesselink
Journal:  Pediatr Nephrol       Date:  2010-07-22       Impact factor: 3.714

6.  Clinical polymorphism of cystinosis encephalopathy. Results of treatment with cysteamine.

Authors:  M Broyer; M J Tête; G Guest; J P Berthélémé; F Labrousse; M Poisson
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

Review 7.  Nephropathic cystinosis: late complications of a multisystemic disease.

Authors:  Galina Nesterova; William Gahl
Journal:  Pediatr Nephrol       Date:  2008-06       Impact factor: 3.714

8.  Effects of cysteamine on oxidative status in cerebral cortex of rats.

Authors:  Adriana Kessler; Micheli Biasibetti; Luciane Rosa Feksa; Virginia Cielo Rech; Denizar Alberto da Silva Melo; Moacir Wajner; Carlos Severo Dutra-Filho; Angela Terezinha de Souza Wyse; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2007-11-21       Impact factor: 3.584

9.  Developmental changes in cerebral white matter microstructure in a disorder of lysosomal storage.

Authors:  Sunita Bava; Rebecca J Theilmann; Miriam Sach; Susanne J May; Lawrence R Frank; John R Hesselink; Duc Vu; Doris A Trauner
Journal:  Cortex       Date:  2009-04-05       Impact factor: 4.027

10.  Cysteamine prevents inhibition of thiol-containing enzymes caused by cystine or cystine dimethylester loading in rat brain cortex.

Authors:  Virginia Cielo Rech; Luciane Rosa Feksa; Rochele Marisa Müller Fleck; Genaro Azambuja Athaydes; Paula Karina Barcelos Dornelles; Valnes Rodrigues-Junior; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2008-04-17       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.